(Q28302829)

inferred from title

cognitive dysfunction

1 reference

15

0 references

Teodoro Del Ser

Teodoro del Ser

10

0 references

Sibel Tekin

Sibel Tekin

7

0 references

Howard Feldman

Howard H Feldman

1

0 references

Steven G. Potkin

Steven Potkin

18

0 references

Steven H Ferris

Steven Ferris

2

0 references

Alistair Burns

Alistair Burns

8

0 references

Nick C. Fox

Nick C Fox

20

0 references

Philip Scheltens

14

Philip Scheltens

0 references

Bengt Winblad

3

Bengt Winblad

0 references

Jeffrey L. Cummings

9

Jeffrey Cummings

0 references

Martin R. Farlow

17

Martin Farlow

0 references

author name string

Nikolaos Sfikas

4

0 references

Linda Mancione

5

0 references

Yunsheng He

6

0 references

Domenico Inzitari

11

0 references

Jean-Marc Orgogozo

12

0 references

Heinrich Sauer

13

0 references

Nathan Herrmann

16

0 references

H Cecil Charles

19

0 references

Roger Lane

Mild Cognitive Impairment

21

0 references

language of work or name

English

0 references

publication date

June 2007

0 references

published in

Lancet Neurology

0 references

volume

6

0 references

page(s)

501-12

0 references

issue

6

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970109-6

7 January 2021

Mild cognitive impairment: clinical characterization and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970109-6

7 January 2021

Mild Cognitive Impairment Can Be Distinguished From Alzheimer Disease and Normal Aging for Clinical Trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970109-6

7 January 2021

Current concepts in mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970109-6

7 January 2021

Vascular risk factors, incidence of MCI, and rates of progression to dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970109-6

7 January 2021

Incidence and outcome of mild cognitive impairment in a population-based prospective cohort.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970109-6

7 January 2021

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970109-6

7 January 2021

The cholinergic deficit coincides with Abeta deposition at the earliest histopathologic stages of Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970109-6

7 January 2021

Imaging of nicotinic and muscarinic receptors in Alzheimer's disease: effect of tacrine treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970109-6

7 January 2021

Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970109-6

7 January 2021

Mitogen-activated protein kinase-dependent and protein kinase C-dependent pathways link the m1 muscarinic receptor to beta-amyloid precursor protein secretion

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970109-6

7 January 2021

Loss of nucleus basalis neurons containing trkA immunoreactivity in individuals with mild cognitive impairment and early Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970109-6

7 January 2021

Beta-amyloid peptides as direct cholinergic neuromodulators: a missing link?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970109-6

7 January 2021

Vitamin E and donepezil for the treatment of mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970109-6

7 January 2021

Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970109-6

7 January 2021

The Clinical Dementia Rating (CDR): current version and scoring rules

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970109-6

7 January 2021

Neuropsychological prediction of decline to dementia in nondemented elderly

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970109-6

7 January 2021

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970109-6

7 January 2021

Development of a Rating Scale for Primary Depressive Illness

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970109-6

7 January 2021

Cued recall in amnesia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970109-6

7 January 2021

Screening for dementia by memory testing

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970109-6

7 January 2021

The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970109-6

7 January 2021

Screening for Alzheimer's disease by clock drawing.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970109-6

7 January 2021

Clock drawing in Alzheimer's disease. A novel measure of dementia severity.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970109-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970109-6

1 reference

7 January 2021

The Global Deterioration Scale for assessment of primary degenerative dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970109-6

7 January 2021

A new clinical scale for the staging of dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970109-6

7 January 2021

Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970109-6

7 January 2021

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970109-6

7 January 2021

Assessing quality of life in older adults with cognitive impairment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970109-6

7 January 2021

Brain atrophy progression measured from registered serial MRI: validation and application to Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970109-6

7 January 2021

Apolipoprotein E epsilon4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970109-6

7 January 2021

Rate of progression of cognitive decline in Alzheimer's disease: effect of butyrylcholinesterase K gene variation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970109-6

7 January 2021

Targeting acetylcholinesterase and butyrylcholinesterase in dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970109-6

7 January 2021

Mutagenically separated PCR (MS-PCR): a highly specific one step procedure for easy mutation detection

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970109-6

7 January 2021

Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970109-6

7 January 2021

Mild cognitive impairment is associated with characteristic neuropsychiatric symptoms.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970109-6

7 January 2021

Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970109-6

7 January 2021

Risk factors for mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 2.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970109-6

7 January 2021

Increased acetylcholinesterase activity in the CSF of Alzheimer patients carrying apolipoprotein epsilon4 allele.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970109-6

7 January 2021

Apolipoprotein E, cholesterol transport and synthesis in sporadic Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970109-6

7 January 2021

Apolipoprotein E: a major piece in the Alzheimer's disease puzzle.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970109-6

7 January 2021

Clinical trials in mild cognitive impairment: lessons for the future

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970109-6

7 January 2021

Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970109-6

7 January 2021

Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970109-6

7 January 2021